AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
-52.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
5 quarters
Since Q1 2025
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -52.0% | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -19.0% | -34.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -55.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -30.0% | – | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 15.0% | – | Form 6-K FY2025Q1 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%) (%), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_beyfortus_world_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.